• DS-TMD shows no DNA rearrangements and a low rate of mutations other than GATA1
Introduction
Children with Down syndrome (DS) have 10-50 fold higher incidence of leukaemias than euploid children, including most types of acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL) 1,2 3 . Acute megakaryoblastic leukaemia (AMKL), which is preceded by transient myeloproliferative disorder (TMD), has a 500-fold increased incidence relative to euploid children 4 . DS-TMD/AMKL is a unique condition of DS that enables the study of stages of leukaemogenesis, beginning in the fetus as pre-cancerous hyperproliferation that manifests itself as TMD in the first weeks postnatally and which thereafter regresses spontaneously to complete remission 5, 6 . In 20-30% of cases of regressed DS-TMD, the dormant clonal TMD is thought to accumulate additional changes, and 1-4 years later cause AMKL , and as the presence or type of GATA1 mutations does not predict the outcome of TMD (spontaneous regression or progression to AMKL) 5, 9 , it remains unclear whether GATA1 mutations represent the first initiating event sufficient for the onset of TMD in T21 cells, or whether other acquired changes are preceding or accompanying it, such as mutations in JAK2, JAK3, TP53 and FLT3 5, 11, 12 that have been observed together with GATA1 mutations, at various stages of this disease.
It has been suggested that GATA1 controls proliferation of hematopoietic progenitors through repression of a MYC transcription factor 13, 14 . It has been shown in megakaryocyte progenitors that the truncated form, GATA1s, fails to properly downregulate MYC, which results in substantially elevated (up to 10 fold) levels of MYC expression 13, 15 . Nevertheless, despite substantial efforts in recent years, the nature of affected pathways that drive the progression of DS-TMD to DS-AMKL, and their association with the loss of full length GATA1 protein, remain elusive 6 . In order to address this question we have analyzed mutational profiles of DS-TMDs and DS-AMKLs using exome sequencing, as well as (somatic) copy number alterations (SCNAs) restricted to DS-AMKL samples using genomewide SNP microarrays. This study reveals driver mutations and SCNAs common to other
For personal use only. on April 21, 2017. by guest www.bloodjournal.org From Genome-wide SNP microarray analysis: in all cases (10 DS-TMDs, 7 DS-AMKLs and 2 remission controls of DS-AMKLs) the Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA) was used to screen for Somatic Copy Number Alterations (SCNA).
Genome-wide SNP-array hybridization was performed with 500ng gDNA following the manufacturer's instructions. Genome-wide copy number analysis was performed using the Affymetrix Genotyping Console version 4.0 and the Affymetrix Genotyping Console Browser version 1.10.12, and a reference set of 47 in-house control DNAs isolated from blood of healthy donors, none of which presented with any type of leukaemia.
Results
We performed the exome-sequencing of 10 samples from 7 ML-DS patients, of which 5 were DS-TMDs, 3 were DS-AMKLs (including one paired TMD-AMKL patient), and 2 were complete remission controls of the other two DS-AMKLs (Table 1, Supplementary Table 2 ).
In addition, a high-resolution analysis for somatic copy number alterations (SCNA) on 10 DS-TMD and 7 DS-AMKL samples (including also the exome-sequenced series) using Affymetrix 6.0 arrays that combine 1.9 million SNP and copy number probes genome-wide was performed. For one patient (patient 4) both TMD and AMKL stages of the disease were exome-sequenced (TMD4→AMKL4). The samples and experiments are summarised in Table 1 .
DS-AMKL is characterized by additional "driver" mutations and SCNAs common with other types of leukaemia.
In all DS-AMKL cases where both exome sequencing and high-resolution SCNA analysis were performed, we could identify mutations/deletions in genes proven as functional "drivers" of tumourigenesis in non-DS leukaemia ( Figure 1 , Table 2 ).
In AMKL4 (Table 3) we identified several putative "driver" mutations in addition to GATA1 mutations, all of which were absent at TMD stage (TMD4). Among these mutations there was a frameshift insertion in EZH2 (p.D674_Y675delinsX) (Figure 2 ). This mutation is a known recurrent mutation (COSMIC ID: 52999) in patients with myeloid disorders 18, 19 ; moreover mono-or biallelic EZH2 mutations were detected in 12% of myeloproliferative disorders 18, 19 . We also have detected a p.G1118R mutation in SMC3 which was found to be recurrently mutated in AMLs 20 . Both EZH2 and SMC3 encode the proteins involved in chromatin remodelling 20, 21 . Another candidate "driver" mutation (p.E178K) was observed in DHX29, a gene previously reported to be associated with cancerogenic pathways in non- Mbp, and a 37 Mbp segment, see Figure 3 ), intriguingly, neither of these deleted segments overlapped the two critical deleted regions on Chr5q in non-DS myeloid leukaemias 23 (Table   1 ). The larger of the two deleted regions in AMKL4 did however encompass the tumour suppressor APC gene, deleted in up to 15% of non-DS AMLs 24 .
Patient 15 was diagnosed with AMKL at the age of 17 months. All the somatic events detected in the AMKL15 were absent in the remission sample. This leukaemia harbours one additional copy of chromosome 21 (tetrasomy 21) and two extra copies of chromosome 14 (tetrasomy 14). Chromosome 21 has three copies of one allele and one copy of the second allele; chromosome 14 has two copies of each allele (Tables 1 and 2 ). Additionally, we detected a sub-microscopic 6.2 Mbp deletion on Chr8q, that harbours only 4 genes: CSMD3, TRP51, EXT1 and SAMD12 (Supplementary Figure S1A) . Interestingly, EXT1 could be considered as a putative driver gene since it was found that EXT1 CpG island hypermethylation was common in leukaemia, especially in acute promyelocytic leukaemia and in acute lymphoblastic leukaemia, and non-melanoma skin cancer 25 ( Figure 1 ). We also have found a putative driver mutation in DLEC1 (p.D1772delD) which have been already reported for an AML case 26 and in kidney tumour (COSMIC ID: COSM308378), moreover epigenetic silencing of this gene was detected in the majority of Hodgkin and non-Hodgkin lymphomas 27 .
Patient 16 was diagnosed with AMKL at age 21 months. We were able to identify several putative driver mutations in addition to GATA1, all of which were absent in the remission sample (Table 2) : one was a mutation in JAK1 p.S703T (COSMIC ID: COSM96541), which has been already observed in lymphoblastic leukaemias 28,29 ( Figure 1 , Table 2 ). Another was a putative driver p.R976L mutation in the POLE gene encoding the polymerase epsilon, which is involved in defective DNA mismatch repair pathway (MMR). AMKL16 has also acquired several chromosomal abnormalities affecting chromosomes other than Chr21:
balanced LOH in 3q (starting at Mbp 109), this region includes two small deletions, furthermore a small likely homozygous deletion was identified on chromosome 3p including coding exons of the gene FHIT. Chromosomal rearrangements in chromosome 7 resulting in one copy of 7p arm and in 3 copies of 7q arm, most likely due to isochromosome 7q as well as a submicroscopic deletions on Chr6. Chromosomal aberrations in chromosome 3 and chromosome 7 are frequently detected in leukaemias. A deletion on Chr6 involved 3 genes two of which were PARK2 and PACRG (Supplementary Figure S1B) , whose common promoter was found frequently abnormally methylated, resulting in downregulation of gene 
DS-TMD: low mutation-rates and intact genome integrity
In 5 TMD samples analysed by exome-sequencing, between 1-3 mutations were detected, including different GATA1 mutations in the same patient (Supplementary Table 3 ). In 2/5 TMD cases (TMD3 and TMD4) we detected mutations other than GATA1 (Tables 1 and   2 ).These data indicate very low mutation rates in DS-TMDs. None of the 10 DS-TMD DNA samples showed any SCNAs by high-resolution SNP and CNV array analysis (Table 1 ). In AMKL4, two SCNAs observed at the AMKL stage of the disease (deletions of two regions on 5q) were not present at the TMD stage (TMD4) (Figure 3 ). This suggests that segmental chromosomal instability is not a major contributing factor to the pathogenesis of DS-TMD.
Another recent study [Blink et al. 2012] mentions that 4/7 DS-TMD cases did show some SCNAs (lower than DS-AMKLs), but no patient details or data were shown for a detailed comparison with our study 31 .
DS-AMKL: mutation-rates typical of leukaemia and high chromosomal instability
DS-AMKLs studied here harbour a few somatic coding mutations in the whole exome (between 8 and 14; Supplementary Table 3) indicating that mutation rates are comparable with the other types of leukaemia 20, 32, 33 . On the other hand, high-resolution SCNA analysis using genome-wide combined SNP/CNV array has revealed multiple acquired segmental gains, losses or LOH events in 6/7 DS-AMKL cases (Table 1) which is concordant with the previous observations in DS-AMKLs and is higher than in other paediatric AML subgroups, with the exception of non-DS AMKL 31, 34 . In the single case where no SCNAs were found (AMKL25), karyotyping revealed a balanced translocation t(X;16)(q26;q23).
GATA1 mutations are often sole acquired events in DS-TMD
We performed conventional sequencing of the second exon (and neighbouring introns) of the GATA1 gene, and found, as expected, typical GATA1 mutations in all DS-TMD and all DS-AMKL cases (Table1, Supplementary (Figures 1,2 ).
Patient 4 was diagnosed with TMD as a neonate at 8 days of age, and after spontaneous regression, 24 months later the disease had progressed to AMKL (sample AMKL4). In TMD4 we have detected two distinct mutations in the 2nd exon of GATA1 (20nt insertion and 12nt deletion) as well as a nonsense mutation in PIK3C2A (p.R1461X) ( Table 3 ). In AMKL4 only one of these mutations, namely the 12nt deletion in GATA1 was present, suggesting that: (i) the two GATA1 mutations in TMD4 represent different megakaryoblastic clonal populations; and (ii): the 20nt duplication in GATA1 and the mutation in PIK3C2A coexist in the same clone of megakaryoblasts in TMD which eventually self regressed (here: clone A), however the clone with 12nt deletion in GATA1 have progressed to AMKL (here: clone B).
Additional evidence favouring co-localization of GATA1 20nt duplication and PIK3C2A mutation comes from the fact that both mutations were present in TMD in 12% of DNA, as verified by Sanger sequencing. The clone B in TMD4 was characterized by only one GATA1 mutation (12 nt deletion) present in 8% of DNA. However in AMKL4 this clone acquired 7 additional somatic mutations. All these mutations, as well as the GATA1 12 nt deletion, were present in 21-26% of DNA of the AMKL sample as have been validated with Sanger sequencing, which suggests their origin within the same clone of megakaryoblasts.
The facts that truncating GATA1 mutations are invariably associated with DS-TMD and DS-AMKL and that clone B in TMD4 contains only GATA1 mutation, strongly suggest that the GATA1 mutation in the context of T21 is both necessary and sufficient for the clonal expansions presenting as DS-TMD (Figure 1 ).
Given that GATA1 was the first mutation in the clone A of TMD4, and that all cells of this clone contain a PIK3C2A nonsense mutation, we suggest that this mutation provides a selective advantage to these megakaryoblasts over megakaryoblasts with only the GATA1 20 nt duplication. Indeed PIK3C2A is known to be essential for endothelial cell migration, proliferation and survival indicating its putative tumourigenic properties. However, it is not clear from our data if the PIK3C2A p.R1461X mutation is activating or loss of function due to nonsense-mediated decay. Additionally we identified an activating mutation in receptor tyrosine kinase FLT3 (K663N) in TMD12. The presence of additional "driver" mutations in The combined SNP/SCNA analysis revealed multiple acquired segmental gains, losses or LOH events in 6/7 DS-AMKL cases (Table 1 ). In the single case where no SCNAs were found (AMKL25), karyotyping revealed a balanced translocation t(X;16)(q26;q23).
Translocations involving 16q23 have been described in multiple myeloma 41 . The implication of detected SCNAs in AMKLs all of which are common in other types of leukaemia also remains to be investigated (Table 1) . However, the fact that all detected SCNA rendered poor prognosis to the patients with non DS associated leukaemia suggests their causative role in TMD to AMKL progression 23, 30, 42 .
Predicted effects of observed "third-hit-driver" events for DS-AMKL converge on upregulation of MYC
One of the tumourigenic consequences of mutated GATA1 is overexpression of MYC [13] [14] [15] 43 .
We have reasoned that the secondary mutations detected in this study targeting JAK1, APC, Interestingly EZH2, a component of Polycomb repressive complex, found mutated in one patient in this study, is known to be directly controlled by MYC in AMLs 51 .
Our study cannot of course rule out other driver "hits" conferred by epigenetic events. A previous transcriptome comparison found the expression of testis-cancer antigen PRAME as the discriminative marker of DS-AMKL compared to DS-TMD 44 , and the overexpression this gene is known to be due to de-methylation of the regulatory regions, and established as a potential driver event in tumourigenesis 52 and inhibitor of differentiation in myeloid leukaemic precursor cells 53 . Interestingly, overexpression of PRAME was found to be the part of the progression programme for chronic myeloid leukaemia (CML), in synergy with de-regulation of the WNT/beta-catenin pathway 54
Conclusions
In conclusion, our data demonstrate that DS-AMKLs form by accumulation of multiple somatic SCNAs and point mutations in genes known as "drivers" of leukaemogenesis. These putative "driver" events can be detected in every DS-AMKL case, affecting one or more typical leukaemogenic signalling pathways, such as JAK/STAT, MAPK/PI3K and WNT.
GATA1 mutations could be the first, and often sole acquired events in DS-TMD. The DS- 2 .
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A 3 5 . Red boxes indicate regions of somatic copy number alterations (SCNAs) that are detected by differences in allele distribution, and simultaneous loss of probe intensity, i.e. lower log2-ratio. Here 2 deletions are detected on chromosome 5 (chr5:1.4-3.8Mbp and chr5:85.4-
122.1Mbp).
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